{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:39Z","timestamp":1793781879155,"version":"4.6.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41575-023-00854-4","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:02:44Z","timestamp":1699621364000},"page":"86-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Deciphering the different phases of preclinical inflammatory bowel disease"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1438-5106","authenticated-orcid":false,"given":"Jonas J.","family":"Rudbaek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4729-1485","authenticated-orcid":false,"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-5821","authenticated-orcid":false,"given":"Joana","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-2969","authenticated-orcid":false,"given":"Saurabh","family":"Mehandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-7332","authenticated-orcid":false,"given":"Tine","family":"Jess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"854_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427\u2013434 (2007).","journal-title":"Nature"},{"key":"854_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres, J. et al. Crohn\u2019s disease. Lancet 389, 1741\u20131755 (2017).","journal-title":"Lancet"},{"key":"854_CR3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"289","author":"RC Ungaro","year":"2017","unstructured":"Ungaro, R. C. et al. Ulcerative colitis. Lancet 289, 1756\u20131770 (2017).","journal-title":"Lancet"},{"key":"854_CR4","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang, J. T. Pathophysiology of inflammatory bowel diseases. N. Engl. J. Med. 383, 2652\u20132664 (2020).","journal-title":"N. Engl. J. Med."},{"key":"854_CR5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769\u20132778 (2017).","journal-title":"Lancet"},{"key":"854_CR6","doi-asserted-by":"publisher","first-page":"899372","DOI":"10.3389\/fimmu.2022.899372","volume":"13","author":"G Frazzei","year":"2022","unstructured":"Frazzei, G. et al. Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes. Front. Immunol. 13, 899372 (2022).","journal-title":"Front. Immunol."},{"key":"854_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/BOR.0000000000000708","volume":"32","author":"KH Greenblatt","year":"2020","unstructured":"Greenblatt, K. H. et al. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr. Opin. Rheumatol. 32, 289\u2013296 (2020).","journal-title":"Curr. Opin. Rheumatol."},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.rdc.2014.07.004","volume":"40","author":"JM Robertson","year":"2014","unstructured":"Robertson, J. M. & James, J. A. Preclinical systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 40, 621\u2013635 (2014).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"854_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2004.060228","volume":"54","author":"E Israeli","year":"2005","unstructured":"Israeli, E. et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54, 1232\u20131236 (2005).","journal-title":"Gut"},{"key":"854_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ecco-jcc\/jjab048","volume":"15","author":"J Torres","year":"2021","unstructured":"Torres, J. et al. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD \u2014 Prediction and Prevention of Inflammatory Bowel Disease. J. Crohns Colitis 15, 1443\u20131454 (2021).","journal-title":"J. Crohns Colitis"},{"key":"854_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"KM De Lange","year":"2017","unstructured":"De Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256\u2013261 (2017).","journal-title":"Nat. Genet."},{"key":"854_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","volume":"578","author":"DB Graham","year":"2020","unstructured":"Graham, D. B. & Xavier, R. J. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 578, 527\u2013539 (2020).","journal-title":"Nature"},{"key":"854_CR13","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.eclinm.2021.100884","volume":"36","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses. EClinicalMedicine 36, 100884 (2021). Comprehensive systemic review and meta-analysis collecting the available knowledge of early life risk factors and showing the importance of the early life period in the risk of later IBD development.","journal-title":"EClinicalMedicine"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"D Piovani","year":"2019","unstructured":"Piovani, D. et al. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157, 647\u2013659.e4 (2019).","journal-title":"Gastroenterology"},{"key":"854_CR15","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.3748\/wjg.v12.i23.3668","volume":"12","author":"L Halme","year":"2006","unstructured":"Halme, L. et al. Family and twin studies in inflammatory bowel disease. World J. Gastroenterol. 12, 3668\u20133672 (2006).","journal-title":"World J. Gastroenterol."},{"key":"854_CR16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/j.1572-0241.2005.00224.x","volume":"100","author":"T Jess","year":"2005","unstructured":"Jess, T. et al. Disease concordance, zygosity, and NOD2\/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am. J. Gastroenterol. 100, 2486\u20132492 (2005).","journal-title":"Am. J. Gastroenterol."},{"key":"854_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1056\/NEJM199101103240203","volume":"324","author":"M Orholm","year":"1991","unstructured":"Orholm, M. et al. Familial occurrence of inflammatory bowel disease. N. Engl. J. Med. 324, 84\u201388 (1991).","journal-title":"N. Engl. J. Med."},{"key":"854_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979\u2013986 (2015). Large trans-ancestry study that not just discovers new genetic risk loci, but also shows that some genetic heterogeneity is present between divergent populations in some of the risk loci.","journal-title":"Nat. Genet."},{"key":"854_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrgastro.2014.27","volume":"11","author":"J Van Limbergen","year":"2014","unstructured":"Van Limbergen, J. et al. Advances in IBD genetics. Nat. Rev. Gastroenterol. Hepatol. 11, 372\u2013385 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"854_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1365-2796.2007.01809.x","volume":"261","author":"DJP Barker","year":"2007","unstructured":"Barker, D. J. P. The origins of the developmental origins theory. J. Intern. Med. 261, 412\u2013417 (2007).","journal-title":"J. Intern. Med."},{"key":"854_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2249.2010.04263.x","volume":"163","author":"AN Colebatch","year":"2011","unstructured":"Colebatch, A. N. & Edwards, C. J. The influence of early life factors on the risk of developing rheumatoid arthritis. Clin. Exp. Immunol. 163, 11\u201316 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"854_CR22","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.2337\/dc18-1764","volume":"41","author":"M Haupt-J\u00f8rgensen","year":"2018","unstructured":"Haupt-J\u00f8rgensen, M. et al. Maternal antibiotic use during pregnancy and type 1 diabetes in children \u2013 a national prospective cohort study. Diabetes Care 41, e155\u2013e157 (2018).","journal-title":"Diabetes Care"},{"key":"854_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41385-020-0257-y","volume":"13","author":"Z Al Nabhani","year":"2020","unstructured":"Al Nabhani, Z. & Eberl, G. Imprinting of the immune system by the microbiota early in life. Mucosal Immunol. 13, 183\u2013189 (2020).","journal-title":"Mucosal Immunol."},{"key":"854_CR24","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.14309\/ajg.0000000000001933","volume":"117","author":"M Agrawal","year":"2022","unstructured":"Agrawal, M. et al. Early-life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 117, 2025\u20132032 (2022).","journal-title":"Am. J. Gastroenterol."},{"key":"854_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/gutjnl-2022-327724","volume":"72","author":"M Agrawal","year":"2023","unstructured":"Agrawal, M. et al. Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study. Gut 72, 804\u2013805 (2023).","journal-title":"Gut"},{"key":"854_CR26","doi-asserted-by":"publisher","first-page":"105676","DOI":"10.1016\/j.envint.2020.105676","volume":"138","author":"M Elten","year":"2020","unstructured":"Elten, M. et al. Ambient air pollution and the risk of pediatric-onset inflammatory bowel disease: a population-based cohort study. Environ. Int. 138, 105676 (2020).","journal-title":"Environ. Int."},{"key":"854_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.14309\/ajg.0000000000000990","volume":"116","author":"M Elten","year":"2021","unstructured":"Elten, M. et al. Residential greenspace in childhood reduces risk of pediatric inflammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol. 116, 347\u2013353 (2021).","journal-title":"Am. J. Gastroenterol."},{"issue":"Suppl. 1","key":"854_CR28","first-page":"i40","volume":"17","author":"SH Lee","year":"2023","unstructured":"Lee, S. H. et al. Peri-natal exposure to parental Crohn\u2019s disease is associated with impaired gut barrier, microbiome composition differences and increased risk of Crohn\u2019s disease [abstract OP29]. J. Crohns Colitis 17 (Suppl. 1), i40\u2013i47 (2023).","journal-title":"J. Crohns Colitis"},{"key":"854_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.gastro.2020.03.040","volume":"159","author":"N Nair","year":"2020","unstructured":"Nair, N. et al. Association between early-life exposures and inflammatory bowel diseases, based on analyses of deciduous teeth. Gastroenterology 159, 383\u2013385 (2020). An interesting study showing the usefulness of an unconventional sample type (deciduous teeth) to investigate environmental exposures and risk of IBD.","journal-title":"Gastroenterology"},{"key":"854_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/gutjnl-2018-317855","volume":"69","author":"J Torres","year":"2020","unstructured":"Torres, J. et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut 69, 42\u201351 (2020).","journal-title":"Gut"},{"key":"854_CR31","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2020.11.050","volume":"160","author":"ES Kim","year":"2021","unstructured":"Kim, E. S. et al. Longitudinal changes in fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies. Gastroenterology 160, 1118\u20131130.e3 (2021).","journal-title":"Gastroenterology"},{"key":"854_CR32","doi-asserted-by":"publisher","first-page":"S465","DOI":"10.14309\/00000434-201010001-01265","volume":"105","author":"IS Soon","year":"2010","unstructured":"Soon, I. S. et al. The relationship between urban environment and inflammatory bowel disease: a systematic review and meta-analysis [abstract 1265]. Am. J. Gastroenterol. 105, S465 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"854_CR33","doi-asserted-by":"publisher","first-page":"e1323","DOI":"10.1016\/j.cgh.2021.08.031","volume":"20","author":"CH Lo","year":"2022","unstructured":"Lo, C. H. et al. Ultra-processed foods and risk of Crohn\u2019s disease and ulcerative colitis: a prospective cohort study. Clin. Gastroenterol. Hepatol. 20, e1323\u2013e1337 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"854_CR34","doi-asserted-by":"publisher","first-page":"n1554","DOI":"10.1136\/bmj.n1554","volume":"374","author":"N Narula","year":"2021","unstructured":"Narula, N. et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. BMJ 374, n1554 (2021).","journal-title":"BMJ"},{"key":"854_CR35","doi-asserted-by":"publisher","first-page":"535\u2013","DOI":"10.1093\/ecco-jcc\/jjac167","volume":"17","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Intake of ultra-processed foods is associated with an increased risk of Crohn\u2019s disease: a cross-sectional and prospective analysis of 187 154 participants in the UK Biobank. J. Crohns Colitis 17, 535\u2013552 (2022).","journal-title":"J. Crohns Colitis"},{"key":"854_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/apt.15770","volume":"51","author":"JE Axelrad","year":"2020","unstructured":"Axelrad, J. E. et al. Systematic review: gastrointestinal infection and incident inflammatory bowel disease. Aliment. Pharmacol. Ther. 51, 1222\u20131232 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"854_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1542-3565(03)00290-8","volume":"2","author":"J Cosnes","year":"2004","unstructured":"Cosnes, J. et al. Gender differences in the response of colitis to smoking. Clin. Gastroenterol. Hepatol. 2, 41\u201348 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"854_CR38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11377-013-0849-0","volume":"9","author":"J Karczewski","year":"2014","unstructured":"Karczewski, J. et al. The effect of cigarette smoking on the clinical course of inflammatory bowel disease. Prz. Gastroenterol. 9, 153\u2013159 (2014).","journal-title":"Prz. Gastroenterol."},{"key":"854_CR39","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4065\/81.11.1462","volume":"81","author":"SS Mahid","year":"2006","unstructured":"Mahid, S. S. et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin. Proc. 81, 1462\u20131471 (2006).","journal-title":"Mayo Clin. Proc."},{"key":"854_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ecco-jcc\/jjac111","volume":"17","author":"J Torres","year":"2023","unstructured":"Torres, J. et al. Risk factors for developing inflammatory bowel disease within and across families with a family history of IBD. J. Crohns Colitis 17, 30\u201336 (2023).","journal-title":"J. Crohns Colitis"},{"key":"854_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/gutjnl-2022-327845","volume":"72","author":"AS Faye","year":"2023","unstructured":"Faye, A. S. et al. Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study. Gut 72, 663\u2013670 (2023).","journal-title":"Gut"},{"key":"854_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/0003-4819-156-5-201203060-00007","volume":"156","author":"AN Ananthakrishnan","year":"2012","unstructured":"Ananthakrishnan, A. N. et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease ulcerative colitis: a cohort study. Ann. Intern. Med. 156, 350\u2013359 (2012).","journal-title":"Ann. Intern. Med."},{"key":"854_CR43","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41586-022-05308-6","volume":"611","author":"LM Sanmarco","year":"2022","unstructured":"Sanmarco, L. M. et al. Identification of environmental factors that promote intestinal inflammation. Nature 611, 801\u2013809 (2022).","journal-title":"Nature"},{"key":"854_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature14232","volume":"519","author":"B Chassaing","year":"2015","unstructured":"Chassaing, B. et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519, 92\u201396 (2015).","journal-title":"Nature"},{"key":"854_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/oemed-2014-102364","volume":"72","author":"K Steenland","year":"2015","unstructured":"Steenland, K. et al. A cohort incidence study of workers exposed to perfluorooctanoic acid (PFOA). Occup. Environ. Med. 72, 373\u2013380 (2015).","journal-title":"Occup. Environ. Med."},{"key":"854_CR46","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1289\/ehp.1206449","volume":"121","author":"K Steenland","year":"2013","unstructured":"Steenland, K. et al. Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the Mid-Ohio Valley. Environ. Health Perspect. 121, 900\u2013905 (2013).","journal-title":"Environ. Health Perspect."},{"key":"854_CR47","doi-asserted-by":"publisher","first-page":"112222","DOI":"10.1016\/j.envres.2021.112222","volume":"207","author":"P Lochhead","year":"2022","unstructured":"Lochhead, P. et al. Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: a nested case control analysis in the Nurses\u2019 Health Study cohorts. Environ. Res. 207, 112222 (2022).","journal-title":"Environ. Res."},{"key":"854_CR48","doi-asserted-by":"publisher","first-page":"100345","DOI":"10.1016\/j.conctc.2019.100345","volume":"14","author":"CK Porter","year":"2019","unstructured":"Porter, C. K. et al. Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: rationale, organization, design, and baseline characteristics. Contemp. Clin. Trials Commun. 14, 100345 (2019).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"854_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida, A. et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin. J. Gastroenterol. 11, 1\u201310 (2018).","journal-title":"Clin. J. Gastroenterol."},{"key":"854_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohn\u2019s disease revealed by a metagenomic approach. Gut 55, 205\u2013211 (2006).","journal-title":"Gut"},{"key":"854_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2180-11-7","volume":"11","author":"AW Walker","year":"2011","unstructured":"Walker, A. W. et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11, 7 (2011).","journal-title":"BMC Microbiol"},{"key":"854_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/gutjnl-2012-303207","volume":"63","author":"MEV Johansson","year":"2014","unstructured":"Johansson, M. E. V. et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63, 281\u2013291 (2014).","journal-title":"Gut"},{"key":"854_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/gut.2006.094375","volume":"56","author":"S Zeissig","year":"2007","unstructured":"Zeissig, S. et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn\u2019s disease. Gut 56, 61\u201372 (2007).","journal-title":"Gut"},{"key":"854_CR54","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1073\/pnas.1407001111","volume":"111","author":"KG Lassen","year":"2014","unstructured":"Lassen, K. G. et al. Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc. Natl Acad. Sci. USA 111, 7741\u20137746 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"854_CR55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/ibd\/izac217","volume":"29","author":"T Breugelmans","year":"2023","unstructured":"Breugelmans, T. et al. Aberrant mucin expression profiles associate with pediatric inflammatory bowel disease presentation and activity. Inflamm. Bowel Dis. 29, 589\u2013601 (2023).","journal-title":"Inflamm. Bowel Dis."},{"key":"854_CR56","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2018.10.046","volume":"156","author":"WT Uniken Venema","year":"2019","unstructured":"Uniken Venema, W. T. et al. Single-cell RNA sequencing of blood and ileal T cells from patients with Crohn\u2019s disease reveals tissue-specific characteristics and drug targets. Gastroenterology 156, 812\u2013815.e22 (2019).","journal-title":"Gastroenterology"},{"key":"854_CR57","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","volume":"28","author":"M Uzzan","year":"2022","unstructured":"Uzzan, M. et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat. Med. 28, 766\u2013779 (2022).","journal-title":"Nat. Med."},{"key":"854_CR58","doi-asserted-by":"publisher","first-page":"893803","DOI":"10.3389\/fimmu.2022.893803","volume":"13","author":"V van Unen","year":"2022","unstructured":"van Unen, V. et al. Identification of a disease-associated network of intestinal immune cells in treatment-naive inflammatory bowel disease. Front. Immunol. 13, 893803 (2022).","journal-title":"Front. Immunol."},{"key":"854_CR59","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1053\/j.gastro.2020.08.005","volume":"159","author":"W Turpin","year":"2020","unstructured":"Turpin, W. et al. Increased intestinal permeability is associated with later development of Crohn\u2019s disease. Gastroenterology 159, 2092\u20132100.e5 (2020). This prospective study, which was performed in pre-Crohn\u2019s disease FDRs and healthy FDRs, is the first to our knowledge to show that abnormal intestinal permeability seems to be present prior to onset of Crohn\u2019s disease.","journal-title":"Gastroenterology"},{"key":"854_CR60","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1053\/j.gastro.2020.12.004","volume":"160","author":"HJ Galipeau","year":"2021","unstructured":"Galipeau, H. J. et al. Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology 160, 1532\u20131545 (2021). This study shows that functional changes in the intestinal environment, in the form of increased proteolytic activity, which is associated with changes in the microbial composition, can be found several years prior to the onset of ulcerative colitis in FDRs.","journal-title":"Gastroenterology"},{"key":"854_CR61","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/MIB.0000000000000323","volume":"21","author":"D Kevans","year":"2015","unstructured":"Kevans, D. et al. Determinants of intestinal permeability in healthy first-degree relatives of individuals with Crohn\u2019s disease. Inflamm. Bowel Dis. 21, 879\u2013887 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"854_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/gut.44.1.96","volume":"44","author":"JD S\u00f6derholm","year":"1999","unstructured":"S\u00f6derholm, J. D. et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn\u2019s disease: an inherited defect in mucosal defence? Gut 44, 96\u2013100 (1999).","journal-title":"Gut"},{"key":"854_CR63","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bbi.2012.04.001","volume":"26","author":"S Leclercq","year":"2012","unstructured":"Leclercq, S. et al. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain. Behav. Immun. 26, 911\u2013918 (2012).","journal-title":"Brain. Behav. Immun."},{"key":"854_CR64","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/ibd\/izz116","volume":"25","author":"W Turpin","year":"2019","unstructured":"Turpin, W. et al. Analysis of genetic association of intestinal permeability in healthy first-degree relatives of patients with Crohn\u2019s disease. Inflamm. Bowel Dis. 25, 1796\u20131804 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"854_CR65","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/ecco-jcc\/jjab064","volume":"15","author":"M Nighot","year":"2021","unstructured":"Nighot, M. et al. Matrix metalloproteinase MMP-12 promotes macrophage transmigration across intestinal epithelial tight junctions and increases severity of experimental colitis. J. Crohns Colitis 15, 1751\u20131765 (2021).","journal-title":"J. Crohns Colitis"},{"key":"854_CR66","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1136\/gutjnl-2022-328421","volume":"72","author":"H Leibovitzh","year":"2023","unstructured":"Leibovitzh, H. et al. Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn\u2019s disease highlight earliest events of pathogenesis. Gut 72, 1462\u20131471 (2023). This study combines findings of disease-associated serum protein markers with markers of subclinical inflammation, humoral response to microbial antigens and intestinal barrier properties, therefore giving insight into the links between these different pathways.","journal-title":"Gut"},{"key":"854_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41564-021-01050-3","volume":"7","author":"RH Mills","year":"2022","unstructured":"Mills, R. H. et al. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat. Microbiol. 7, 262\u2013276 (2022).","journal-title":"Nat. Microbiol."},{"key":"854_CR68","doi-asserted-by":"publisher","first-page":"7531","DOI":"10.3748\/wjg.v19.i43.7531","volume":"19","author":"IM Carroll","year":"2013","unstructured":"Carroll, I. M. & Maharshak, N. Enteric bacterial proteases in inflammatory bowel disease \u2013 pathophysiology and clinical implications. World J. Gastroenterol. 19, 7531\u20137543 (2013).","journal-title":"World J. Gastroenterol."},{"key":"854_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000199640","volume":"40","author":"JGH Ruseler-van Embden","year":"1988","unstructured":"Ruseler-van Embden, J. G. H. & Van Lieshout, L. M. C. Increased proteolysis and leucine aminopeptidase activity in faeces of patients with Crohn\u2019s disease. Digestion 40, 33\u201340 (1988).","journal-title":"Digestion"},{"key":"854_CR70","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1136\/gutjnl-2013-306226","volume":"63","author":"CR Hedin","year":"2014","unstructured":"Hedin, C. R. et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn\u2019s disease and their unaffected siblings. Gut 63, 1578\u20131586 (2014).","journal-title":"Gut"},{"key":"854_CR71","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/gutjnl-2014-308896","volume":"65","author":"C Hedin","year":"2016","unstructured":"Hedin, C. et al. Siblings of patients with Crohn\u2019s disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities. Gut 65, 944\u2013953 (2016).","journal-title":"Gut"},{"key":"854_CR72","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcmgh.2016.06.004","volume":"2","author":"JP Jacobs","year":"2016","unstructured":"Jacobs, J. P. et al. A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients. Cell. Mol. Gastroenterol. Hepatol. 2, 750\u2013766 (2016).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"854_CR73","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1053\/j.gastro.2023.05.032","volume":"165","author":"JA Raygoza Garay","year":"2023","unstructured":"Raygoza Garay, J. A. et al. Gut microbiome composition is associated with future onset of Crohn\u2019s disease in healthy first-degree relatives. Gastroenterology 165, 670\u2013681 (2023). To our knowledge, the first study showing an association between preclinical changes in the microbial composition and later Crohn\u2019s disease onset.","journal-title":"Gastroenterology"},{"key":"854_CR74","doi-asserted-by":"publisher","first-page":"858902","DOI":"10.3389\/fcimb.2022.858902","volume":"12","author":"ZJ Dong","year":"2022","unstructured":"Dong, Z. J., Lv, W. Q., Zhang, C. Y. & Chen, S. Correlation analysis of gut microbiota and serum metabolome with Porphyromonas gingivalis-induced metabolic disorders. Front. Cell Infect. Microbiol. 12, 858902 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"854_CR75","doi-asserted-by":"publisher","first-page":"2104089","DOI":"10.1080\/19490976.2022.2104089","volume":"14","author":"G Liu","year":"2022","unstructured":"Liu, G. et al. Gut dysbiosis impairs hippocampal plasticity and behaviors by remodeling serum metabolome. Gut Microbes 14, 2104089 (2022).","journal-title":"Gut Microbes"},{"key":"854_CR76","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/ecco-jcc\/jjaa227","volume":"15","author":"K Gallagher","year":"2021","unstructured":"Gallagher, K. et al. Metabolomic analysis in inflammatory bowel disease: a systematic review. J. Crohns Colitis 15, 813\u2013826 (2021).","journal-title":"J. Crohns Colitis"},{"key":"854_CR77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.gastro.2022.09.007","volume":"164","author":"X Hua","year":"2023","unstructured":"Hua, X. et al. Inflammatory bowel disease is associated with prediagnostic perturbances in metabolic pathways. Gastroenterology 164, 147\u2013150.e2 (2023).","journal-title":"Gastroenterology"},{"key":"854_CR78","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1053\/j.gastro.2021.07.009","volume":"161","author":"SH Lee","year":"2021","unstructured":"Lee, S. H. et al. Anti-microbial antibody response is associated with future onset of Crohn\u2019s disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk. Gastroenterology 161, 1540\u20131551 (2021).","journal-title":"Gastroenterology"},{"key":"854_CR79","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1053\/j.gastro.2022.05.029","volume":"163","author":"A Mortha","year":"2022","unstructured":"Mortha, A. et al. Neutralizing anti-granulocyte macrophage-colony stimulating factor autoantibodies recognize post-translational glycosylations on granulocyte macrophage-colony stimulating factor years before diagnosis and predict complicated Crohn\u2019s disease. Gastroenterology 163, 659\u2013670 (2022). A comprehensive study showing that autoantibodies targeting GM-CSF are elevated up to 6 years before Crohn\u2019s disease onset, and furthermore these autoantibodies specifically target an altered post-translational glycosylation on GM-CSF, thereby suggesting that changes in glycosylation might be associated with disease development.","journal-title":"Gastroenterology"},{"key":"854_CR80","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos, A. E. et al. Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164, 619\u2013629 (2023). This study in two independent cohorts is the first to show that autoantibodies targeting integrin \u03b1v\u03b26 are associated with later disease onset of ulcerative colitis, and that the presence of these antibodies can predict later disease onset.","journal-title":"Gastroenterology"},{"key":"854_CR81","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2012-302717","volume":"62","author":"FDM Van Schaik","year":"2013","unstructured":"Van Schaik, F. D. M. et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 62, 683\u2013688 (2013).","journal-title":"Gut"},{"key":"854_CR82","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","volume":"159","author":"J Torres","year":"2020","unstructured":"Torres, J. et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 159, 96\u2013104 (2020). This large retrospective case\u2013control study with longitudinal sampling identified a panel of protein markers and serum antibodies that are predictive of Crohn\u2019s disease development within 5 years.","journal-title":"Gastroenterology"},{"key":"854_CR83","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.13641","volume":"43","author":"RS Choung","year":"2016","unstructured":"Choung, R. S. et al. Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis. Aliment. Pharmacol. Ther. 43, 1300\u20131310 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"854_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.01.033","author":"RS Choung","year":"2023","unstructured":"Choung, R. S. et al. Preclinical serological signatures are associated with complicated Crohn\u2019s disease phenotype at diagnosis. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2023.01.033 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"854_CR85","doi-asserted-by":"publisher","first-page":"890522","DOI":"10.3389\/fimmu.2022.890522","volume":"13","author":"MY Choi","year":"2022","unstructured":"Choi, M. Y. & Costenbader, K. H. Understanding the concept of pre-clinical autoimmunity: prediction and prevention of systemic lupus erythematosus: identifying risk factors and developing strategies against disease development. Front. Immunol. 13, 890522 (2022).","journal-title":"Front. Immunol."},{"key":"854_CR86","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese, E. M. & Firestein, G. S. Rheumatoid arthritis \u2013 common origins, divergent mechanisms. N. Engl. J. Med. 388, 529\u2013542 (2023).","journal-title":"N. Engl. J. Med."},{"key":"854_CR87","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1038\/ctg.2015.49","volume":"6","author":"C Melinder","year":"2015","unstructured":"Melinder, C. et al. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin. Transl. Gastroenterol. 6, e121\u2013e128 (2015).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"854_CR88","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cgh.2016.01.016","volume":"14","author":"P Lochhead","year":"2016","unstructured":"Lochhead, P., Khalili, H., Ananthakrishnan, A. N., Richter, J. M. & Chan, A. T. Association between circulating levels of C-reactive protein and interleukin-6 and risk of inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 14, 818\u2013824.e6 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"854_CR89","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1053\/j.gastro.2021.07.026","volume":"161","author":"D Bergemalm","year":"2021","unstructured":"Bergemalm, D. et al. Systemic inflammation in preclinical ulcerative colitis. Gastroenterology 161, 1526\u20131539.e9 (2021).","journal-title":"Gastroenterology"},{"key":"854_CR90","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","volume":"15","author":"C Reily","year":"2019","unstructured":"Reily, C. et al. Glycosylation in health and disease. Nat. Rev. Nephrol. 15, 346\u2013366 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"854_CR91","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41575-020-0331-7","volume":"17","author":"MR Kudelka","year":"2020","unstructured":"Kudelka, M. R. et al. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. Nat. Rev. Gastroenterol. Hepatol. 17, 597\u2013617 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"854_CR92","doi-asserted-by":"publisher","first-page":"102804","DOI":"10.1016\/j.autrev.2021.102804","volume":"20","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Antibody glycosylation in autoimmune diseases. Autoimmun. Rev. 20, 102804 (2021).","journal-title":"Autoimmun. Rev."},{"key":"854_CR93","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/art.40920","volume":"71","author":"L Hafenscheid","year":"2019","unstructured":"Hafenscheid, L. et al. N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheumatol. 71, 1626\u20131633 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"854_CR94","doi-asserted-by":"publisher","first-page":"eabo1930","DOI":"10.1126\/scitranslmed.abo1930","volume":"15","author":"I Alves","year":"2023","unstructured":"Alves, I. et al. Host-derived mannose glycans trigger a pathogenic \u03b3\u03b4 T cell\/IL-17a axis in autoimmunity. Sci. Transl. Med. 15, eabo1930 (2023).","journal-title":"Sci. Transl. Med."},{"key":"854_CR95","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1007\/s10620-010-1434-8","volume":"55","author":"M Pham","year":"2010","unstructured":"Pham, M. et al. Subclinical intestinal inflammation in siblings of children with Crohn\u2019s disease. Dig. Dis. Sci. 55, 3502\u20133507 (2010).","journal-title":"Dig. Dis. Sci."},{"key":"854_CR96","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0016-5085(03)00383-4","volume":"124","author":"B Thjodleifsson","year":"2003","unstructured":"Thjodleifsson, B. et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn\u2019s disease relatives? Gastroenterology 124, 1728\u20131737 (2003).","journal-title":"Gastroenterology"},{"key":"854_CR97","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1572-0241.2006.00884.x","volume":"102","author":"M Montalto","year":"2007","unstructured":"Montalto, M. et al. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am. J. Gastroenterol. 102, 132\u2013136 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"854_CR98","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cgh.2019.05.061","volume":"18","author":"KM Taylor","year":"2020","unstructured":"Taylor, K. M. et al. Genetic and inflammatory biomarkers classify small intestine inflammation in asymptomatic first-degree relatives of patients with Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 18, 908\u2013916.e13 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"854_CR99","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/j.gastro.2019.11.006","volume":"158","author":"J Torres","year":"2020","unstructured":"Torres, J. Prediction of inflammatory bowel disease: a step closer? Gastroenterology 158, 278\u2013279 (2020).","journal-title":"Gastroenterology"},{"key":"854_CR100","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s10620-022-07714-2","volume":"38","author":"NA Cohen","year":"2023","unstructured":"Cohen N. A., et al. Trends in biochemical parameters, healthcare resource and medication use in the 5 years preceding IBD diagnosis: a Health Maintenance Organization Cohort Study. Dig. Dis. Sci. 38, 414\u2013422 (2023).","journal-title":"Dig. Dis. Sci."},{"key":"854_CR101","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/ibd\/izz265","volume":"26","author":"K Vadstrup","year":"2020","unstructured":"Vadstrup, K. et al. Cost burden of Crohn\u2019s disease and ulcerative colitis in the 10-year period before diagnosis \u2013 a Danish register-based study from 2003\u20132015. Inflamm. Bowel Dis. 26, 1377\u20131382 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"854_CR102","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.cgh.2017.11.006","volume":"16","author":"I Rodr\u00edguez-Lago","year":"2018","unstructured":"Rodr\u00edguez-Lago, I. et al. Characteristics and progression of preclinical inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 16, 1459\u20131466 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"854_CR103","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.dld.2020.05.052","volume":"52","author":"I Rodr\u00edguez-Lago","year":"2020","unstructured":"Rodr\u00edguez-Lago, I. et al. Early microscopic findings in preclinical inflammatory bowel disease. Dig. Liver Dis. 52, 1467\u20131472 (2020).","journal-title":"Dig. Liver Dis."},{"key":"854_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ueg2.12352","volume":"11","author":"I Rodr\u00edguez-Lago","year":"2023","unstructured":"Rodr\u00edguez-Lago, I. et al. Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease. United European Gastroenterol. J. 11, 9\u201318 (2023). Retrospective case\u2013control study showing that individuals who later develop IBD have elevated usage of steroids and increased health-care utilization 3 and 5 years before diagnosis of disease.","journal-title":"United European Gastroenterol. J."},{"key":"854_CR105","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ecco-jcc\/jjaa146","volume":"15","author":"J Blackwell","year":"2021","unstructured":"Blackwell, J. et al. Prevalence and duration of gastrointestinal symptoms before diagnosis of inflammatory bowel disease and predictors of timely specialist review: a population-based study. J. Crohns Colitis 15, 203\u2013211 (2021).","journal-title":"J. Crohns Colitis"},{"key":"854_CR106","doi-asserted-by":"crossref","unstructured":"Bonfils, L. et al. Medication use is increased in the decade prior to IBD diagnosis: a nationwide cohort study [abstract DOP62]. Presented at the 18th Congress of the European Crohn\u2019s and Colitis Organisation. https:\/\/www.ecco-ibd.eu\/publications\/congress-abstracts\/item\/dop62-medication-use-is-increased-in-the-decade-prior-to-ibd-diagnosis-a-nationwide-cohort-study.html (2023). A large population-based study showing that usage of a broad spectrum of medication types is increased in the 10 years leading up to disease onset in patients with IBD.","DOI":"10.1093\/ecco-jcc\/jjac190.0102"},{"key":"854_CR107","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/art.1780311004","volume":"31","author":"AD Puente","year":"1988","unstructured":"Puente, A. D. et al. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 31, 1239\u20131244 (1988).","journal-title":"Arthritis Rheum."},{"key":"854_CR108","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MMJ Nielen","year":"2004","unstructured":"Nielen, M. M. J. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380\u2013386 (2004).","journal-title":"Arthritis Rheum."},{"key":"854_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035296","volume":"7","author":"J Sokolove","year":"2012","unstructured":"Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (2012).","journal-title":"PLoS ONE"},{"key":"854_CR110","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaut.2016.06.001","volume":"74","author":"R Lu","year":"2016","unstructured":"Lu, R. et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74, 182\u2013193 (2016).","journal-title":"J. Autoimmun."},{"key":"854_CR111","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ebiom.2019.03.063","volume":"42","author":"JA James","year":"2019","unstructured":"James, J. A. et al. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine 42, 76\u201385 (2019).","journal-title":"EBioMedicine"},{"key":"854_CR112","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/art.27533","volume":"62","author":"A Ercan","year":"2010","unstructured":"Ercan, A. et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 62, 2239\u20132248 (2010).","journal-title":"Arthritis Rheum."},{"key":"854_CR113","doi-asserted-by":"publisher","first-page":"673708","DOI":"10.3389\/fimmu.2021.673708","volume":"12","author":"Y Kinashi","year":"2021","unstructured":"Kinashi, Y. & Hase, K. Partners in leaky gut syndrome: intestinal dysbiosis and autoimmunity. Front. Immunol. 12, 673708 (2021).","journal-title":"Front. Immunol."},{"key":"854_CR114","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603\u2013613 (2019).","journal-title":"N. Engl. J. Med."},{"key":"854_CR115","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-023-01847-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Teplizumab: first approval. Drugs 83, 439\u2013445 (2023).","journal-title":"Drugs"},{"key":"854_CR116","doi-asserted-by":"publisher","first-page":"103217","DOI":"10.1016\/j.autrev.2022.103217","volume":"22","author":"G Frazzei","year":"2023","unstructured":"Frazzei, G. et al. Prevention of rheumatoid arthritis: a systematic literature review of preventive strategies in at-risk individuals. Autoimmun. Rev. 22, 103217 (2023).","journal-title":"Autoimmun. Rev."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00854-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00854-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00854-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T14:03:43Z","timestamp":1706796223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00854-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1038\/s41575-023-00854-4","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"3 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. has received research grants from Genentech and Takeda; payment for lectures from Genentech, Morphic and Taleda; and consulting fees from Arena Pharmaceuticals, Ferring, Morphic and Takeda. J.-F.C. has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire and Takeda; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix and Vifor; and holds stock options in Intestinal Biotech Development. J.T. has received research grants from AbbVie and Janssen Pharmaceuticals; has received advisory board fees from AbbVie, Janssen Pharmaceuticals, Pfizer and BMS; and has received speaker fees from AbbVie, Janssen Pharmaceuticals and Pfizer. J.J.R., M.A. and T.J. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}